IRF5, Additional Targets — Initial data
H2 2026
o Third internally-developed program: Phase 1 clinical data is anticipated in the second half of 2026.Source filing
ALMS biotech catalysts & pipeline
ALUMIS INC · Data as of 2026-10-25
Upcoming catalysts
envudeucitinib — NDA/BLA submission
in 4Q 2026
– On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026Source filing